Comparative Study Between Combined Oral Contraceptive Pills (OCP) and Dienogest on Pain Management in Endometriosis
Observational
OA: bronze
CC0
AI-generated summary
Dienogest offered superior pain relief and quality-of-life improvements compared to combined oral contraceptive pills for women with endometriosis over a six-month period.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Background: Endometriosis is a common estrogen-dependent inflammatory disorder affecting women of reproductive age, causing dysmenorrhea, chronic pelvic pain and dyspareunia that substantially impair quality of life. Hormonal suppression with combined oral contraceptive pills (OCPs) and dienogest is a widely used medical therapy, yet comparative evidence on their relative efficacy for pain relief remains limited, particularly in South Asian populations. Objective: This study aimed to compare the effectiveness of combined OCP and dienogest in relieving pain and improving quality of life among women with endometriosis over a six-month treatment period. Methods: This retrospective observational study was conducted at the Department of Reproductive Endocrinology and Infertility, Bangladesh Medical University, between February 2023 and January 2024, involving 80 women with laparoscopically confirmed endometriosis divided into combined OCP (n=40) and dienogest (n=40) groups. Pain scores for dysmenorrhea, chronic pelvic pain and dyspareunia were assessed using a visual analogue scale and quality of life was measured using the Endometriosis Health Profile-30 (EHP-30) questionnaire at baseline and six months. Statistical analysis was performed using SPSS version 25.0. Results: Both groups showed significant pain reduction after six months; however, dienogest produced a greater decline in dysmenorrhea (2.4±1.2 vs 3.6±1.4, p<0.001), chronic pelvic pain (2.3±1.1 vs 3.2±1.5, p=0.006) and dyspareunia (2.2±1.3 vs 3.1±1.6, p=0.007), together with better EHP-30 scores (39.8±10.6 vs 46.5±11.4, p=0.008). A greater proportion of women achieved at least 50% dysmenorrhea reduction with dienogest (87.5% vs 70.0%, p=0.048). Irregular bleeding was more frequent with dienogest, whereas nausea and breast tenderness were more common with combined OCP. Conclusion: Dienogest provides superior pain relief and quality-of-life improvement compared with combined OCP in endometriosis management, with a distinct but manageable adverse-effect profile.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- openalex
- last seen: 2026-10-16T06:01:16.192504+00:00
License: CC0
· commercial use OK